Advertisement


Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

2024 ASCO Annual Meeting

Advertisement

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The KEYNOTE study is actually the study that established first-line combination VEGF-TKI, lenvatinib, and PD-1 inhibitor, pembrolizumab, as a standard therapy in metastatic renal cell cancer. The study has met several endpoint, progression-free survival, overall survival, and response rate showing that the combination of pembrolizumab and lenvatinib is superior to sunitinib. And here, what we did during the 2024 ASCO, great meeting by the way, we looked at baseline PD-L1 expression by immunohistochemistry, specific gene alteration by interrogating whole exome, and gene expression pattern using RNA-Seq. We did not have samples on all the patient from the full analysis, but the large subset we had on had similar baseline characteristic as the whole cohort. What we concluded is the combination of lenvatinib and pembrolizumab does work irrespective of PD-L1 immunohistochemistry. It showed that it worked and had a longer progression-free survival and improved response rate over sunitinib regardless of specific kidney cancer driver gene alteration, and these driver gene alteration are essentially the top mutated gene in kidney cancer, VHL, PBRM1, [inaudible 00:01:37], BAP1, KDM5C, but the combination is superior to sunitinib irrespective. And finally, we did look at a specific molecular subtype and gene expression, but the gene expression where the past several years reported specific to renal cell or not, but we looked at specific signature for renal cell cancer, the clusters, and universally, it showed that pembrolizumab-lenvatinib does work irrespective of any molecular subtypes, whether it's the angiogenesis subtype, the immune proliferative, et cetera. We will continue trying to find biomarkers specific to one therapy, and despite that this is a bit on the negative side, I think it's important to show that what doesn't work as biomarker as important show what does work.

Related Videos

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.

Breast Cancer

Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study

Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).

Breast Cancer

Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease

Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence, including patients with node-negative disease, and showed a benefit in invasive disease–free survival (Abstract 512).

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Advertisement

Advertisement




Advertisement